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A B S T R A C T
The current meta-analysis summarizes relevant literature on earlier (P100, N100, P200, N200, ERN/Ne) versus
later (P300, Pe, CNV) cognitive Event-Related Potential (ERP) differences between children, adolescents, and
adults with Attention-Deficit/Hyperactivity Disorder (ADHD) and without ADHD (non-ADHD). Furthermore, the
heterogeneity in previous research is addressed by analyzing potentially relevant demographic and methodo-
logical moderators (age group, IQ, medication, comorbidity, task, cognitive function, modality, inter-stimulus-
interval, number of electrodes). Via database search 52 relevant articles were identified including n=1576
ADHD and n=1794 non-ADHD. Using multilevel-models, pooled effect sizes were calculated. For earlier
components, individuals with ADHD showed shorter Go-P100-latencies than non-ADHD. For later ERPs, in-
dividuals with ADHD showed smaller Cue-P300-amplitudes, longer Go-P300-latencies, smaller NoGo-P300-
amplitudes, longer NoGo-P300-latencies, smaller CNV-amplitudes, and smaller Pe-amplitudes. The substantial
heterogeneity identified for most of the ERP components could be explained by the demographic and metho-
dological moderators of interest. This meta-analysis identified relevant moderate group differences
(−0.32< d<−0.57), mainly regarding later cognitive ERPs. Nevertheless, results are characterized by sub-
stantial heterogeneity and the moderate effect sizes (d<0.6) limit the use for clinical application.
1. Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most
prevalent neurodevelopmental disorders characterized by core symp-
toms of age-inappropriate levels of inattention, hyperactivity, and im-
pulsivity (Biederman and Faraone, 2005; Taylor et al., 2004). With a
prevalence of approximately 5 % (Polanczyk et al., 2015) and a per-
sistence rate of 30–40 % into adulthood (Faraone et al., 2006), it is
considered as a major public health problem due to the significant so-
cial and educational disadvantage of the affected patients (Lesesne
et al., 2000; Swanson et al., 1998). Several findings have already em-
phasized the biological underpinnings of ADHD (Thome et al., 2012).
The study of biological markers in individuals with ADHD represents an
important path towards understanding the clinically and etiologically
heterogeneous nature of this neurodevelopmental disorder and its
therapeutic outcomes (Faraone et al., 2014). While no single reliable
biomarker for the diagnosis of ADHD exists to date, some promising
candidate brain-based biomarkers have been discussed (Gamma and
Kara, 2016). For instance, Event-Related Potentials (ERPs) during re-
sponse inhibition and response control have been widely examined in
ADHD (Gamma and Kara, 2016; Johnstone et al., 2013; Thome et al.,
2012; see Szuromi et al., 2011 for a quantitative review on adult ADHD
P300-differences).
1.1. Previous findings on event-related potentials in ADHD
Cognitive ERPs represent stimulus-locked time epochs in the elec-
troencephalogramm (EEG). They offer a unique window into the brain
and represent promising tools for exploring the biological basis of
cognitive functioning in ADHD due to their ease of administration, their
functional relevance, and their high time-resolution (Lenartowicz and
Loo, 2014). As cognitive ERPs are defined by the time they occur after
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stimulus presentation in the task-related EEG, they can be divided into
earlier (P100, N100, P200, N200, ERN/Ne) and later (P300, CNV, Pe)
components reflecting the time course of task-related neural informa-
tion-processing. For the current meta-analysis and in line with cognitive
models of ADHD (e.g. Kofler et al., 2019), cognitive ERPs including
sensory components with prominent cognitive modulation are in the
focus of interest. Very early components reflecting mainly sensory
processing, such as brain stem potentials or the P50 indexing sensory
gating (e.g. Micoulaud-Franchi et al., 2015), were excluded. We also
excluded the Mismatch Negativity (MMN) component that specifically
assesses the integrity of automatic auditory-sensory memory and in-
voluntary attentional switches outside the focus cognitive tasks. This
component had been analyzed in a previous meta-analysis in children
with ADHD (Cheng et al., 2016), suggesting a reduced MMN amplitude
Table 1
Overview of ERP components and their mental processing correlates.
ERP component Mental processing correlates
P100a Spatial attention; gating to stimulus location (Luck et al., 2000)
N100b Spatial attention; orienting response; matching processes with previously experiences stimuli; processing of unexpected stimuli (Luck et al., 1990; Sur and
Sinha, 2009)
P200a Attention to/processing of visual stimuli; sensation-seeking (Sur and Sinha, 2009)
N200b Processing of deviant stimuli; classification of stimulus (Sur and Sinha, 2009)
P300a Stimulus processing & evaluation of task-relevance (Cortese, 2012); updating of working memory, event categorization, attentional resource allocation, and
attentional reorientation (Polich, 2007)
CNVb Stimulus expectation; motor and non-motor preprocessing after cue stimulus (Walter et al., 1964)
ERN/Neb Error detection; error correction (Coles and Rugg, 1995)
Pea Error processing (Nieuwenhuis et al., 2001)
a Positive wave/deflection.
b Negative wave/deflection.
Fig. 1. Flow chart displaying the literature selection process according to PRISMA guidelines (Moher et al., 2009).
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compared to children without ADHD. For a description of relevant ERP
components addressed within the current analysis and their neu-
ropsychological equivalent reflecting cognitive activation or modula-
tion, see Table 1.
Several studies have documented robust neurophysiological differ-
ences between individuals with ADHD and individuals without ADHD
(non-ADHD), especially for later ERPs, including lower NoGo-P300-
amplitudes in individuals with ADHD over central regions during au-
ditory and visual response-control tasks compared to non-ADHD chil-
dren and adolescents, as well as reduced CNV-amplitudes in ADHD (e.g.
reviewed in Barry et al., 2003). Regarding earlier ERPs during execu-
tive-control tasks, results are less consistent and more depending on
potential influence variables: while several studies report on abnorm-
alities of the N200-component (e.g. Albrecht et al., 2005; Pliszka et al.,
2000; Tamayo-Orrego et al., 2015), others indicate that these only
occur under specific task-conditions (e.g. Yong-Liang et al., 2000).
Extensive research has examined ERP differences between in-
dividuals with ADHD and individuals without ADHD, but until now
there is no quantitative summary of previous literature systematically
analyzing ERPs as possible markers of ADHD across the lifespan capi-
talizing on the high time resolution of ERPs by specifically taking into
account differences between effects on earlier and later cognitive ERPs.
1.2. Potential sources of heterogeneity
The partly inconsistent findings described above might reflect the
substantial heterogeneity of patient samples with ADHD (Lenartowicz
and Loo, 2014): individual characteristics, such as age, IQ, medication
status, symptom severity or the presence of comorbid disorders might
influence neurophysiological processing (Bresnahan et al., 1999; Loo
et al., 2013). Furthermore, methodological variations between the
studies might contribute to the heterogeneity in previous findings.
These include the specific task used to assess cognitive functioning,
task-specific variations, such as the modality of stimulus presentation or
the Inter-Stimulus-Interval (ISI) as well as technical, EEG-related be-
tween-study differences, such as the number of electrodes used to assess
neurophysiological processing (e.g. Yong-Liang et al., 2000). To clarify
the impact of demographic and methodological between-study differ-
ences, a systematic quantitative analysis on these potentially relevant
moderator variables is urgently needed.
Based on previous qualitative and quantitative reviews (Gamma and
Kara, 2016; Johnstone et al., 2013; Szuromi et al., 2011; Thome et al.,
2012), a meta-analysis was conducted summarizing relevant literature
on ERP differences in children, adolescents, and adults with ADHD
compared to individuals without ADHD. The focus was on identifying
group-level differences regarding earlier (P100, N100, P200, N200,
ERN/Ne) versus later (P300, CNV, Pe) cognitive ERP components
(amplitudes and latencies) during inhibitory control, attention, working
memory, and performance monitoring using a quantitative approach.
The main aim is to clarify when the most robust neurophysiological
deviations occur in individuals with ADHD in the time course of cog-
nitive processing covered by task-related ERPs. Generally, we assume
smaller ERP components and longer ERP latencies in individuals with
ADHD when compared to individuals without ADHD reflecting in-
efficient cognitive modulation in neuropsychological processing, espe-
cially during later processing-stages. Furthermore, the current work
aimed at addressing the heterogeneity found in previous research by
defining (based on previous studies) and analyzing (partly in an ex-
plorative way) potentially relevant demographic (age group, IQ, med-
ication, comorbidities) and methodological (task, cognitive function
assessed by task, modality of stimulus presentation, inter-stimulus-in-
terval, number of electrodes used for analysis) moderators.
Table 2
Description of included trials: Demographic information (across all ERP com-
ponents).
ADHD Non-ADHD t df p




Age (years), M (SD) 15.52 (8.53) 15.45 (8.16) 0.04 104 0.96
Male (%), M (SD) 82.26 (17.12) 74.90 (20.90) 1.91 92 0.06
IQ, M (SD) 103.06 (7.10) 110.14 (6.37) −4.23 63 < .0001
Note. Results for Welch-two-sample t-test (between-group comparison).
Table 3
Overall mean estimated true effect sizes for random-effects models/multilevel linear models.
Amplitude Latency
ERP component k d [95% CI] QW (df, p) k d [95% CI] QW (df, p)
Cue trials
P100 k ≤ 1 n.a. n.a. n.a. k ≤ 1 n.a. n.a. n.a.
N100 k ≤ 1 n.a. n.a. n.a. k ≤ 1 n.a. n.a. n.a.
P200 k ≤ 1 n.a. n.a. n.a. k ≤ 1 n.a. n.a. n.a.
N200 k ≤ 1 n.a. n.a. n.a. k ≤ 1 n.a. n.a. n.a.
P300 18 −0.56*** [-0.82 – (-0.30)] 22.04 (17, .18) 2 −0.35 [-0.80 – 0.10] 2.96 (1, .09)
Go trials
P100 10 0.41 [-0.69 – 1.50] 61.80 (9, < .0001) 10 −0.33** [-0.53 – (-0.13)] 8.28 (9, .51)
N100 14 −0.41 [-0.94 – 0.12] 68.41 (13, < .0001) 13 −0.03 [-0.40 – 0.34] 31.16 (12, .002)
P200 16 0.49 [-0.24 – 1.23] 95.68 (15, < .0001) 15 0.01 [-0.83 – 0.86] 106.20 (14, < .0001)
N200 48 0.14 [-0.08 – 0.35] 126.58 (47, < .0001) 31 −0.36 [-1.01 – 0.30] 140.36 (30, < .0001)
P300 76 −0.14 [-0.32 – 0.04] 216.96 (75, < .0001) 38 0.52* [0.08 – 0.96] 201.33 (37, < .0001)
NoGo trials
P100 2 −0.19 [-0.58 – 0.19] 0.01 (1, .93) 3 −0.13 [-0.48 – 0.22] 0.35 (2, .84)
N100 5 −0.11 [-0.38 – 0.17] 6.54 (4, .16) 6 0.04 [-0.22 – 0.30] 5.26 (5, .39)
P200 4 0.03 [-0.32 – 0.37] 7.63 (3, 0.05) 5 0.05 [-0.67 – 0.77] 10.65 (4, .03)
N200 16 0.08 [-0.19 – 0.36] 34.76 (15, .00) 5 −0.59 [-2.49 – 1.32] 38.52 (4, < .0001)
P300 37 −0.57*** [-0.90 – (-0.24)] 95.73 (36, < .0001) 9 0.35** [0.11 – 0.58] 16.85 (8, .03)
CNV 15 0.32* [0.03 – 0.61] 45.99 (14, < .0001) k ≤ 1 n.a. n.a. n.a.
ERN/Ne 23 0.21 [-0.06 – 0.47] 69.52 (22, < .0001) 12 0.04 [-0.40 – 0.48] 26.02 (11, .01)
Pe 23 −0.39** [-0.64 – (-0.13)] 58.33 (22, < .0001) 8 −0.01 [-0.40 – 0.39] 7.37 (7, .39)
Note. *** p < .001, ** p < .01, * p < .05, ° p < .1. n.a. not available.
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2. Methods
2.1. Literature search and selection criteria
The current meta-analysis was registered on PROSPERO (http://
www.crd.york.ac.uk/PROSPERO/display_record.php?ID=
CRD42018098992).
The literature search was performed in line with the PRISMA-
Statement (Moher et al., 2009), incorporating two different search
strategies: An initial search was performed using the databases MED-
LINE (via PubMed), PsychINFO, PsychARTICLES, Cochrane Central,
and Clinical Trials. The subsequent keywords were entered: ADHD
Fig. 2. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to Cue P300 amplitude data and addressing multilevel
structure. Note. Multiple listings of the same study reflect different electrode localizations.
Fig. 3. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to Go P100 latency data and addressing multilevel structure.
Note. Multiple listings of the same study reflect different electrode localizations.
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(separately) combined with EEG or ERP (for more detailed information,
see Appendix A in Supplementary material). The literature search was
started in January 2018 and originally finished in April 2018. An up-
date of the literature search was done in April 2019, but no new studies
were relevant for inclusion. Second, additional records were identified
by reviewing the reference lists of the papers included via the database
search.
All studies identified were screened and assessed for eligibility ac-
cording to the following inclusion/exclusion criteria:
(a) Reporting of quantitative data to compare ERP-markers of cognitive
modulation between children, adolescents, and adults with and
without ADHD.
(b) Administration of an EEG while participants engage in tasks in-
volving inhibitory control, (selective) attention, working memory,
and error monitoring to assess relevant ERPs.
(c) Examination of a group of individuals without ADHD compared to
children, adolescents, and/or adults with ADHD.
(d) Formal diagnosis of ADHD according to only one of the following
criteria: DSM-III-R, DSM-IV, DSM-IV-TR, DSM-V, or ICD-10 (refers
to ADHD as hyperkinetic disorder; HKD).
(e) Study in one of the following languages: English, German, French,
or Spanish.
(f) No case studies or review articles.
(g) Published study between January 1987 (publication year of DSM-
III-R) and April 2018.
Fig. 4. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to Go P300 latency data and addressing multilevel structure.
Note. Multiple listings of the same study reflect different age groups (Taylor et al., 1997) or electrode localizations.
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(h) Sufficient information to calculate the effect size.
A total of 984 potentially relevant studies were identified.1 Fig. 1
provides an overview of the search process and the number of records
included through each of the before mentioned search strategies. Fi-
nally, the literature search resulted in 52 studies for inclusion (Tamayo-
Orrego et al., 2015)2. An asterisk in the reference list marks the in-
cluded articles.
2.2. Data coding
A coding sheet was implemented to record all relevant variables
(see Appendix B in Supplementary material). The relevant information
was extracted from the articles and coded by the first and second au-
thor, independently from each other. Disagreement (< 5 %) was re-
solved in discussion.
The data sheets including the coded information used for sub-
sequent analyses can be found in Appendix C in Supplementary mate-
rial.
Fig. 5. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to NoGo P300 amplitude data and addressing multilevel
structure. Note. Multiple listings of the same study reflect different ADHD subtypes (Rodriguez et al., 2007) or electrode localizations.
1 After de-duplication
2One further study had to be excluded as the type of ERP indices reported
could not be integrated into quantitative analyses.
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2.3. Statistical analyses
For all analyses conducted, the metafor package (Viechtbauer, 2010;
metafor Version 2.0.0, released on 22/06/2017) for R (R Development
Core Team, 2018; R Version 3.5.1.) was used.
The standardized mean difference (d) in ERP amplitudes3 and
latencies between individuals with and without ADHD was computed as
the relevant effect size measure (ADHD minus non-ADHD; Hedges and
Olkin, 1985). Effect sizes were not recoded to have all expected effects
in the same direction. For amplitudes of positive ERPs, negative effect
sizes indicate smaller amplitudes in the ADHD group compared to non-
ADHD. For amplitudes of negative ERPs, positive effect sizes indicate
Fig. 6. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to NoGo P300 latency data and addressing multilevel
structure. Note. Multiple listings of the same study reflect different ADHD subtypes (Rodriguez et al., 2007) or electrode localizations.
Fig. 7. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to CNV amplitude data and addressing multilevel structure.
Note. Multiple listings of the same study reflect different electrode localizations.
3 Group mean amplitudes (of individual peak latencies, peak amplitudes or
mean amplitudes) are included as dependent variables of interest, as they are
(footnote continued)
commonly reported.
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smaller amplitudes in the ADHD group. For ERP latencies, positive
mean effect sizes are associated with longer latencies in the ADHD
group compared to non-ADHD. All effect sizes were calculated using
exact statistics reported in the included studies. For each ERP compo-
nent, a mean effect size was computed for the difference in amplitude
and latency. Furthermore, effect sizes were calculated separately for
each condition (Cue vs. Go vs. NoGo4) for the following ERP compo-
nents: N100, P100, N200, P200, P300.
Multilevel models based on random-effects assumptions were fitted
to the data to estimate the true mean effect sizes. Random-effects
models were chosen because they allow for unconditional inferences
above the specific study implementations (Borenstein et al., 2010).
Multilevel models were implemented to address dependencies due to a
multilevel structure in the data (more than one ES per study in same
analysis e.g. due to more than one age group or neural activity on more
than one electrode location assessed; Viechtbauer, 2010). For the esti-
mation of the mean effect sizes, studies were weighted using the het-
eroscedastic sampling variance. To explore moderator effects, mixed-
effects models were fitted to the data.
As an indicator of heterogeneity, the chi-square statistic Q
(Cochrane`s Q-test; Hedges and Olkin, 1985) was calculated. The QW
statistic obtained in the moderator analyses represents the residual
heterogeneity after taking into account a moderator effect. The QB
statistic refers to the test of a specific moderator. For estimating the
amount of heterogeneity in the effect size distribution, the Restricted
Maximum Likelihood (REML) estimator was used.
Furthermore, sensitivity analyses were conducted to test for the
robustness of effects. To address the potential presence of publication
bias, trim-and-fill analyses were calculated.
3. Results
3.1. Study characteristics
Characteristics of the included studies can be found in Table S1
(Appendix D in Supplementary material). A summary of demographic
Fig. 8. Cumulative forest plot displaying meta-analytical results obtained from fitting multilevel models to Pe amplitude data and addressing multilevel structure.
Note. Multiple listings of the same study reflect different electrode localizations.
4 Cue, Go, and NoGo represent different task conditions. Cue – Cue stimulus
presented to signal upcoming task, typically before target or NoGo stimulus. Go
– Target stimulus presented that requires response (e.g. motor). NoGo –
Stimulus presented that requires to inhibit prepared or prepotent response (e.g.
motor).
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study characteristics across all ERP components (P100, N100, P200,
N200, P300, CNV, ERN/Ne, Pe), conditions (Cue versus Go versus
NoGo), and dependent variables (amplitude versus latency) is presented
in Table 2 (a summary of methodological characteristics can be found
in Table S2; Appendix E in Supplementary material. Table S3 (Appendix
E in Supplementary material) displays the relevant demographic char-
acteristics separately for each ERP component, condition, and each
dependent variable.
3.2. Overall mean effects
Overall mean estimated effect sizes obtained from fitting multilevel
models and corresponding heterogeneity estimates are presented in
Table 3.
3.2.1. Cue condition
For the P300-amplitude, the analysis reveals a significant negative
mean estimated effect size (d=-0.56 [-0.82 – (-0.30)]), indicating a
smaller Cue-P300-amplitude in ADHD compared to non-ADHD. The
P300-latency analysis resulted in a non-significant negative mean effect
size. Fig. 2 displays the forest plot for the Cue-P300-amplitude5 .
3.2.2. Go condition
Significant mean estimated effect sizes were obtained for the P100-
latency (d=-0.33 [-0.53 – (-0.13)]), and the P300-latency (d=0.52
[0.08 – 0.96]), indicating shorter Go-P100-latencies, and longer Go-
P300-latencies in ADHD compared to non-ADHD. Regarding other ERP
components, no significant group differences emerged. Figs. 3 and 4
show the forest plots for significant results obtained for the Go condi-
tion.
3.2.3. NoGo condition
The P300-amplitude (d= -0.57 [-0.90 – (-0.24)]) and the P300-la-
tency components (d=0.35 [0.11 – 0.58]) resulted in significant mean
group differences. For the P300-amplitude, the results indicate that
individuals with ADHD overall present with smaller P300-amplitudes
compared to non-ADHD. The P300-latency results reveal a significantly
higher mean latency in ADHD compared to non-ADHD. For other NoGo-
ERP components, the results did not reach significance. The forest plots
for the significant NoGo condition results can be found in Figs. 5 and 6.
3.2.4. CNV
A significant mean estimated effect size emerged for the CNV-am-
plitude (d=0.32 [0.03 – 0.61]), indicating smaller CNV-amplitudes in
ADHD compared to non-ADHD. Fig. 7 shows the forest plot for the CNV-
amplitude component.
3.2.5. ERN/Ne, Pe
A significant mean group difference emerged for the Pe-amplitude
(d=-0.39 [-0.64 – (-0.13)]), indicating smaller Pe-amplitudes in ADHD
compared to non-ADHD. No further significant results could be ob-
tained. Fig. 8 shows the forest plot for the Pe-amplitude component.
The forest plots for all non-significant results can be found in
Appendix F in Supplementary material. Furthermore, Appendix G in
Supplementary material presents the funnel plots for all ERP
Table 4a
Summary of meta-analytic findings for amplitude moderator analyses (mixed-effects models fitted) – P100, N100, P200.
Cue Go NoGo
Amplitude k QB(df, p) QW(df, p) Comparison k QB(df, p) QW(df, p) Comparison k QB(df, p) QW(df, p) Comparison
P100
age n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
IQ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
medication n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
task n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
cogn. function n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
N100
age n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
IQ n.a. n.a. n.a. n.a. 8 5.48 (1,.02) 30.67 (6, < .0001) n.a. n.a. n.a. n.a. n.a.
medication n.a. n.a. n.a. n.a. 14 34.02 (3, < .0001) 28.67 (11,.003) 2 < 3 < 1*** (neg) n.a. n.a. n.a. n.a.
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
task n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a. 14 6.42 (2, .04) 59.13 (12, < .0001) 2 < 1* (neg) n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. 14 7.57 (1, .006) 54.05 (12, < .0001) n.a. n.s. n.s. n.s. n.a.
P200 .
age n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
IQ n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
medication n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
task n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
Note. n.a. not available. n.s. not significant. Pos – positive ES. Neg – negative ES. Medication moderator: 1 – medicated; 2 – not medicated; 3 – washout period of 24 h;
4 – washout period of 48 h. Comorbidity moderator: 1 – yes, comorbid disorder present; 2 – no, no comorbid disorder present. Cognitive function moderator: 1 –
Inhibition; 2 – Attention; 3 – Working memory; 4 – Error processing. Modality moderator: 1 – visual; 2 – auditory; 3 – multimodal.
5 Some studies provide more than one effect size for ERP analyses reflecting
distinct demographic (e.g. more than one age group assessed) and methodo-
logical aspects (e.g. ERP assessed at several different electrode positions). See
Appendix C for a detailed presentation of demographic and methodological
detail.
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Table 4b
Summary of meta-analytic findings for amplitude moderator analyses (mixed-effects models fitted) –N200, P300.
Cue Go NoGo
Amplitude k QB(df, p) QW(df, p) Comparison k QB(df, p) QW(df, p) Comparison k QB(df, p) QW(df, p) Comparison
N200
age n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
IQ n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
medication n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
task n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.




n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
P300
age 18 19.62 (3,.001) 14.81 (15,
0.47)
Adolescents* < Children** <
Adults** (neg)
n.s. n.s. n.s. n.a. 37 12.84 (3, .005) 92.85 (34,
< .0001)
Adolescents < Adults < Children** (neg)
IQ n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
medication 18 14.04 (3, .003) 16.46 (15,
0.35)
2 < 4** < 1° (neg) n.s. n.s. n.s. n.a. 35 13.31 (4, .01) 80.40 (31,
< .0001)
3 < 2 < 4 < 1** (neg)




1** < 2*** (neg)




2*** > 1*** (neg) n.s. n.s. n.s. n.a. 37 10.77 (4, .03) 93.92 (33,
< .0001)
1 < 2 < 13 < 3** (neg)
cogn. function 18 18.05 (2, .0001) 16.99 (16,
0.39)
2*** < 1 (neg) n.s. n.s. n.s. n.a. 37 11.12 (2, .004) 94.49 (35,
< .0001)
2 < 1** (neg)
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. 37 9.57 (3, .02) 90.92 (34,
< .0001)
1** < 2 < 3 (neg)
ISI n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
Note. n.a. not available. n.s. not significant. Pos – positive ES. Neg – negative ES. Medication moderator: 1 –medicated; 2 – not medicated; 3 – washout period of 24 h; 4 – washout period of 48 h. Comorbidity moderator: 1
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components, for amplitude and latency, respectively.
3.3. Moderator effects
As suggested by the Q-statistics obtained in the overall analyses,
there is substantial heterogeneity in the distribution of effect sizes. To
explore this heterogeneity, moderator analyses were implemented. Due
to a lack of reporting and many different scales used to assess ADHD
symptom severity, no moderator analysis could be conducted on this
potentially relevant influence variable. As can be seen from Tables
4a–4c and Tables 5a–5c, significant moderator results were identified
for all moderator variables postulated. For all categorical moderators,
subgroup-comparisons are presented within the tables.
3.3.1. Age
For age moderator analyses, larger mean effect sizes were identified
in children compared to adolescents or adults for the NoGo-P300-am-
plitude (QB(2)= 12.84, p= .005), the Pe-amplitude (QB(3)= 10.14,
p= .02), the Go-P100-latency (QB(2)= 13.55, p= .001), the Go-P300-
latency (QB(2)= 10.49, p= .005), and the NoGo-N200-latency (QB
(2)= 22.07, p < .0001). For the Cue-P300-amplitude component on
the contrary, largest mean effect sizes were obtained in adults (QB
(3)= 19.62, p= .001).
3.3.2. IQ
A (marginally) significant positive relationship emerged between IQ
and the sizes of the effects for the Go-P200-latency (QB(1)= 2.71,
p= .10), Go-N200-latency (QB(1)= 3.29, p= .07), Go-N100-ampli-
tude (QB(1)= 5.48, p= .02), NoGo-P200-latency (QB(1)= 7.27,
p= .007), Go-N100-latency (QB(1)= 9.17, p= .003), NoGo-N200-la-
tency, (QB(1)= 32.84, p < .0001).
3.3.3. Medication status
A significant association between the medication status of the
ADHD group and the mean size of the effect was obtained for the fol-
lowing components: NoGo-P300-latency (QB(2)= 7.46, p= .02),
NoGo-P300-amplitude (QB(4)= 13.31, p= .01), Cue-P300-amplitude
(QB(4)= 14.04, p= .003), Go-P100-latency (QB(2)= 11.42, p= .003),
Go-N100-amplitude (QB(3)= 34.02, p < .0001), and Pe-amplitude
(QB(4)= 31.03, p < .0001).
3.3.4. Comorbidity
For comorbidity, a significant influence on mean effect size was
obtained for the Go-P300-latency (QB(2)= 6.58, p= .04), the Pe-am-
plitude (QB(2)= 6.34, p= .04), the Go-P100-latency (QB(2)= 7.69,
p= .02), the NoGo-N200-latency (QB(2)= 7.64, p= .02), the NoGo-
P300-amplitude (QB(2)= 41.17, p < .0001), and the CNV-amplitude
(QB(2)= 46.14, p < .0001) component,
3.3.5. Task
A significant moderator effect for task was revealed for the fol-
lowing ERPs: NoGo-P300-latency (QB(3)= 7.94, p= .05), Go-N100-
latency (QB(4)= 10.26, p= .04), CNV-amplitude (QB(4)= 9.85,
p= .04), NoGo-P300-amplitude (QB(4)= 10.77, p= .03), Pe-ampli-
tude (QB(2)= 8.26, p= .02), Go-P100-latency (QB(5)= 17.36,
p= .004), and Cue-P300-amplitude (QB(2)= 17.11, p < .001), with
largest effect sizes for the CPT, the CPT-Flanker version, the Go/NoGo,
and the Oddball task,
3.3.6. Cognitive function
The cognitive function moderator analysis resulted in significant
effects for the the Go-N100-amplitude (QB(2)= 6.42, p= .04), the
NoGo-P300-latency (QB(2)= 7.46, p= .02), and the Pe-amplitude (QB
(2)= 8.24, p= .02), the Go-P100-latency (QB(3)= 12.68, p= .005),
the NoGo-P300-amplitude (QB(2)= 11.12, p= .004), Cue-P300-am-
plitude (QB(2)= 18.05, p= .0001), indicating especially large effect
sizes for tasks assessing inhibition.
3.3.7. Modality
Regarding the modality of stimulus presentation, significant mod-
erator effects were obtained for the following components: NoGo-P300-
amplitude (QB(9)= 9.57, p= .02), NoGo-P300-latency (QB(2)= 9.74,
p= .008), Pe-amplitude (QB(2)= 12.62, p= .002), Go-P100-latency
(QB(2)= 15.39, p= .001), Go-P300-latency (QB(3)= 15.84,
p= .0001), with large effect sizes for auditory stimuli compared to
visual stimuli for the Go-P100-latency, the Go-P300-latency, theNoGo-
P300-amplitude, and the NoGo-P300-latency.
3.3.8. ISI
A significant moderator effect of the ISI on mean effect size was
revealed for the Go-N200-amplitude (QB(1)= 5.86, p= .02), the Pe-
latency (QB(1)= 6.83, p= .009), the CNV-amplitude (QB(1)= 8.30,
p= .004), and the Go-N100-latency (QB(1)= 14.26, p= .0002), all
indicating a small positive relationship between the length of the inter-
stimulus-interval in the task and the size of the mean group difference.
Table 4c
Summary of meta-analytic findings for amplitude moderator analyses (mixed-
effects models fitted) – CNV, ERN/Ne, Pe.
Amplitude k QB(df, p) QW(df, p) Comparison
CNV
age n.s. n.s. n.s. n.a.
IQ n.s. n.s. n.s. n.a.
medication n.s. n.s. n.s. n.a.




2*** < 1 (pos)




1 (pos) < 7 (neg) < 3 (pos)
< 2*
cogn. function n.s. n.s. n.s. n.a.




1° < 2 (pos)





electrodes n.s. n.s. n.s. n.a.
ERN/Ne
age n.s. n.s. n.s. n.a.
IQ n.s. n.s. n.s. n.a.
medication n.s. n.s. n.s. n.a.
comorbidity n.s. n.s. n.s. n.a.
task n.s. n.s. n.s. n.a.
cogn. function n.s. n.s. n.s. n.a.
modality n.s. n.s. n.s. n.a.
ISI n.s. n.s. n.s. n.a.
electrodes n.s. n.s. n.s. n.a.
Pe




Adolescents < Adults° <
Children** (neg)
IQ n.s. n.s. n.s. n.a.




1 (pos) < 4** < 3** < 2*
(neg)




1 < 2* (neg)




13* < 3* (neg)




4* < 1 (neg)




1* < 3* (neg)
ISI n.s. n.s. n.s. n.a.
electrodes n.s. n.s. n.s. n.a.
Note. n.a. not available. n.s. not significant. Pos – positive ES. Neg – negative ES.
Medication moderator: 1 – medicated; 2 – not medicated; 3 – washout period of
24 h; 4 – washout period of 48 h. Comorbidity moderator: 1 – yes, comorbid
disorder present; 2 – no, no comorbid disorder present. Cognitive function
moderator: 1 – Inhibition; 2 – Attention; 3 – Working memory; 4 – Error pro-
cessing. Modality moderator: 1 – visual; 2 – auditory; 3 – multimodal.
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3.3.9. Number of electrodes
For the NoGo-P200-latency (QB(1)= 6.600, p= .01), a significant
positive moderator effect could be obtained, indicating larger effect
sizes with a higher number of electrodes used for the EEG assessment.
On the other hand, for the Go-N100-amplitude (QB(1)= 7.57,
p= .006) a significant negative effect of the moderator was identified:
a higher number of electrodes is associated with smaller effect sizes.
3.4. Sensitivity analyses
Two sensitivity analyses were conducted to compare meta-analytic
results obtained (I) from analyses with and without outlying studies6
and (II) when there was no separation of different conditions (Cue, Go,
NoGo). Results can be found in Tables S4–S97 (Appendix E in Supple-
mentary material). Notably, for the Go-P300-amplitude and the CNV-
amplitude, an even larger negative effect size was obtained after
excluding outlying studies (d=-0.18 [-0.34 – (-0.02)], d=0.41 [0.16 –
0.67], respectively). Furthermore, significant between-group differ-
ences for the overall P300-amplitude (d=-0.25 [-0.43 – (-0.08)]) and
latency analyses (d=0.50 [0.09 – 0.91]) emerged when fitting multi-
level-models across Cue, Go, and NoGo conditions.
3.5. Comparison between earlier and later ERPs
For a direct comparison between earlier and later ERPs, a moderator
analysis was implemented including data for all ERPs per trial condition
(Cue, Go, NoGo8). A significant moderator effect for earlier versus later
ERP components was obtained for the amplitudes of Cue-ERPs (QM
(2)= 123.71, p < .0001), the amplitudes and latencies of Go-ERPs
(QM(7)= 80.65, p < .0001, and QM(7)= 113.24, p < .0001), and the
amplitudes of NoGo-ERPs (QM(7)= 66.03, p < .0001), with sig-
nificant effects for the following ERPs: Cue-P300-amplitude, CNV-am-
plitude, Go-N200-amplitude, Go-P100-amplitude, Pe-amplitude, Go-
N100-latency, Go-P300-latency, and NoGo-P300-amplitude9.
Table 5a
Summary of meta-analytic findings for latency moderator analyses (mixed-effects models fitted) – P100, N100, P200.
Cue Go NoGo
Latency k QB(df, p) QW(df,
p)
Comparison k QB(df, p) QW(df, p) Comparison k QB(df, p) QW(df, p) Comparison
P100 .
age n.a. n.a. n.a. n.a. 10 13.55 (2,
.001)
6.92 (8, 0.55) Adults < Children*** (neg) n.s. n.s. n.s. n.a.
IQ n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
medication n.a. n.a. n.a. n.a. 8 11.42 (2,
.003)
5.70 (6, .46) 3 < 2** (neg) n.s. n.s. n.s. n.a..
comorbidity n.a. n.a. n.a. n.a. 4 7.69 (2, .02) 1.13 (2, .57) 1 < 2** (neg) n.s. n.s. n.s. n.a.
task n.a. n.a. n.a. n.a. 10 17.36 (5,
.004)
3.12 (5, .68) 11 < 5 < 10 < 3 < 6***
(neg)
n.a. n.a. n.a. n.a.
cogn. function n.a. n.a. n.a. n.a. 10 12.68 (3,
.005)
6.73 (7, .46) 3 < 1 < 2*** (neg) n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a. 10 15.39 (2,
.001)
5.09 (8, .75) 1 < 2*** (neg) n.s. n.s. n.s. n.a.
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
N100
age n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
IQ n.a. n.a. n.a. n.a. 8 9.17 (1, .003) 7.90 (6,.25) n.a. n.s. n.s. n.s. n.a.
medication n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a..
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
task n.a. n.a. n.a. n.a. 13 10.26 (4, .04) 14.26 (9, .11) 5 < 1 <3 (neg) < 6* (pos) n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s.
ISI n.a. n.a. n.a. n.a. 9 14.26 (1,
.0002)
7.40 (7, .39) n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
P200
age n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a.. n.s. n.s. n.s. n.a.
IQ n.a. n.a. n.a. n.a. 12 2.71 (1, .10) 37.90 (10, <
.0001)





medication n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a.. n.s. n.s. n.s. n.a..
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
task n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.





Note. n.a. not available. n.s. not significant. Pos – positive ES. Neg – negative ES. Medication moderator: 1 – medicated; 2 – not medicated; 3 – washout period of 24 h;
4 – washout period of 48 h. Comorbidity moderator: 1 – yes, comorbid disorder present; 2 – no, no comorbid disorder present. Cognitive function moderator: 1 –
Inhibition; 2 – Attention; 3 – Working memory; 4 – Error processing. Modality moderator: 1 – visual; 2 – auditory; 3 – multimodal.
6 To determine statistical outliers, plots of the externally standardized re-
siduals and Cook´s distances provided within the R package were examined.
7 1 effect size excluded for: Go-P100-amplitude, N100-amplitude, P200-am-
plitude, P300 latency, NoGo-N100-amplitude, P300-amplitude, P100-latency. 2
effect sizes excluded for: Go-N200-latency, NoGo-N100-latency, and ERN-am-
plitude. 3 effect sizes excluded for Go-P300-amplitude.
8 CNV data were included in the Cue-dataset, while ERN/Ne and Pe data were
included in Go- and NoGo-datasets for comparison.
9Deviations in results (when compared to overall results, separately con-
ducted for each ERP) are due to a larger number of studies.
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3.6. Publication bias analyses
Trim-and-fill analyses calculated to test for publication bias, re-
vealed significant results for the following ERP components: Cue-P300-
amplitude, Go-P200-latency, NoGo-P100-latency, NoGo-N100-latency,
NoGo-P300-amplitude, CNV-amplitude, ERN-amplitude, ERN-latency,
Pe-amplitude, and Pe-latency. For the NoGo-P300-amplitude, a smaller
but still significant effect size emerged when an estimated number of 10
missing studies was imputed, indicating a potential publication bias
(d=-0.30 [-0.48 – (-0.11)]). For the other ERP components, no sig-
nificant results were obtained.
4. Discussion
4.1. Summary of effects: cognitive ERPs as brain-based biomarkers for
ADHD
The current meta-analysis shows significant group-level ERP dif-
ferences between ADHD and non-ADHD, most prominently in later
components. The results indicate that individuals with ADHD show on
average smaller Cue-P300-amplitudes, longer Go-P300-latencies,
smaller NoGo-P300-amplitudes, longer NoGo-P300-latencies, smaller
CNV-amplitudes, and smaller Pe-amplitudes compared to non-ADHD.
In line with current theories on executive functioning deficits in ADHD
(Kofler et al., 2019), the moderate to large effects obtained for these
later components indicate core deficits in later, higher-order cognitive
processing stages and might represent possible biomarkers of ADHD.
Although, a potential publication bias might confound the results ob-
tained for the NoGo-P300-amplitude analyses, the findings of both
sensitivity analyses further support the idea that P300-components are
the most sensitive ADHD-biomarkers.
Unexpectedly, individuals with ADHD also had shorter P100-la-
tencies than non-ADHD. A possible explanation may be that in cogni-
tive paradigms, the later part of the P100 includes higher involvement
of cognitive modulation-processes. Therefore, shorter P100-latencies
might be interpreted as a failure to further engage in such attentional
processing necessary for successful cognitive modulation of sensory
processing (Leroy et al., 2018).
Another unanticipated finding was that the current meta-analysis
could not reliably confirm between-group differences for the N200-
component. As outlined previously, heterogeneous results have been
obtained for N200-alterations in ADHD in primary studies – a finding
also reflected by the significant heterogeneity indices in the current
meta-analysis. As can be seen from the moderator analyses, several
demographic characteristics such as age, IQ, or comorbid disorders
might influence the sensitivity of the N200 as a neurophysiological
marker of ADHD. Therefore, the N200-component might indeed be
relevant for the characterization of subgroups of individuals with
ADHD (e.g. different age groups, IQ levels, with different comorbid-
ities). In addition, non-significant overall results were obtained for the
remaining ERP components: Cue-P300-latency, Go-P100-amplitude,
Go-N100-amplitude and latency, Go-P200-amplitude and latency, Go-
P300-amplitude, NoGo-P100-amplitude and latency, NoGo-N100-am-
plitude and latency, NoGo-P200-amplitude and latency, ERN-amplitude
and latency, as well as the Pe-latency.
Furthermore, the current meta-analyses aimed at addressing sources
of heterogeneity and, to this end, investigated several demographic and
methodological characteristics. The moderator analysis for age group
revealed stronger effects in children compared to adolescents or adults,
for the P100, the N200, the P300, and the Pe components in different
Table 5b






Comparison k QB(df, p) QW(df, p) Comparison k QB(df, p) QW(df, p) Comparison
N200















medication n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a.. n.s. n.s. n.s. n.a..
comorbidity n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. 4 7.64 (2, .02) 1.00 (2,
0.61)
1 (neg) < 2** (pos)
task n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
modality n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
P300






n.a. n.a. n.a. n.a.
IQ n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.a. n.a. n.a. n.a.
medication n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. 9 7.46 (2, .02) 16.75 (7,
.02)
4 < 3* (pos)




2 < 1* (pos) n.a. n.a. n.a. n.a.







n.s. n.s. n.s. n.a. 9 7.94 (3, .05) 16.26 (6,
.01)
2 < 3* < 1 (pos)
cogn. function n.a. n.a. n.a. n.s. n.s. n.s. n.a. 9 7.46 (2, .02) 16.75 (7,
.02)
2 < 1* (pos)




1 (pos) < 3 (neg)
< 2*** (pos)
9 9.74(2, .008) 15.69 (7,
.03)
1* < 2° (pos)
ISI n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
electrodes n.a. n.a. n.a. n.a. n.s. n.s. n.s. n.a. n.s. n.s. n.s. n.a.
Note. n.a. not available. n.s. not significant. Pos – positive ES. Neg – negative ES. Medication moderator: 1 – medicated; 2 – not medicated; 3 – washout period of 24 h;
4 – washout period of 48 h. Comorbidity moderator: 1 – yes, comorbid disorder present; 2 – no, no comorbid disorder present. Cognitive function moderator: 1 –
Inhibition; 2 – Attention; 3 – Working memory; 4 – Error processing. Modality moderator: 1 – visual; 2 – auditory; 3 – multimodal.
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task conditions. This finding is in line with previous literature (e.g.
Johnstone et al., 2007), and might reflect a possible reduction of ADHD
symptoms during adolescence and early adulthood, which is reported to
occur in approximately 40 %–60 % of individuals with ADHD, primarily
for symptoms of hyperactivity (Faraone et al., 2006). However, not all
cognitive ERP alterations were reduced in adults. Consistent with re-
sults from Doehnert and colleagues (Doehnert et al., 2010), the CNV-
amplitude that was reduced in ADHD showed no significant develop-
mental effects, and could therefore be interpreted as a stable neuro-
physiological marker independent of age. For the Cue-P300-amplitude
age-moderator analysis larger group differences were identified for
adults compared to children or adolescents, indicating that the Cue-
P300-component represents a neuromarker candidate for adult ADHD.
Similar meta-analytic results were obtained from Szuromi and collea-
gues (Szuromi et al., 2011) who identified the Go-P300-component as a
brain-based marker for ADHD in adults. As the obtained moderator
effects might also result from a different number of studies included per
age subgroup, they should be interpreted with caution. Nevertheless,
age represents an important moderator that helps to understand phe-
notypic changes in the developmental course of ADHD. Age-related
changes might primarily occur for later ERPs due to more efficient
higher-order cognitive processing, reflected by a normalization of ERP
amplitudes and latencies during the transition from childhood into
early adulthood. Further studies need to explore how these results fit
with models of prefrontal brain maturation in healthy, as well as ADHD
populations. Regarding IQ, the respective moderator analysis indicated
larger between-group differences for higher IQ values. Generally, pri-
mary studies emphasize the protective role of IQ in the developmental
course of psychiatric disorders and for predicting a positive treatment
response, suggesting buffering effects of higher intellectual abilities
(Handen et al., 1997; Owens et al., 2003). Within the current meta-
analysis, larger between-group differences were identified for higher
intellectual abilities (mean across groups). One might assume that these
larger group differences might be due to a lower ability of individuals
with ADHD with higher intellectual abilities to exploit those capacities.
Further studies are warranted to explore IQ-effects in more detail. The
explorative moderator analysis for ADHD medication-status revealed
very heterogeneous results. For some components, larger effects have
been obtained in non-medicated ADHD and ADHD after a washout of
medication compared to medicated ADHD (e.g. Pe-amplitude) – in line
with previous literature reporting on a neurophysiological normal-
ization in individuals with ADHD on appropriate medication (Taylor
et al., 1993). Regarding other ERP components (e.g. Cue- and NoGo-
P300-amplitude), results are mixed and indicate even more elevated
between-group differences between medicated individuals with ADHD
and non-ADHD as compared to unmedicated ADHD or ADHD after a
medication-washout period and non-ADHD. These ERPs might be un-
affected by medication and the medicated ADHD might represent those
more severely affected, resulting in larger neurophysiological differ-
ences. Furthermore, as shown in previous studies, there are substantial
neurophysiological differences between medication responders and
non-responders that might help explaining the current results
(Sunohara et al., 1997). However, for most of the included studies the
information on the type of medication, dosing, and medication response
is lacking and could not be explored. For comorbidity, the results pre-
sent dilution, as well as elevation effects: the presence of comorbid
conditions might result in even smaller or even larger between-group
differences – presumably depending on the different types of co-
morbidities in individuals with ADHD (Rothenberger et al., 2000).
Nevertheless, as for most of the studies the explicit type of comorbidity
is not reported, no detailed analyses could be conducted. For the task-
moderator analysis, four tasks revealed large effect sizes, reflecting
substantial neurophysiological alterations in individuals with ADHD
compared to non-ADHD: the CPT, the CPT-Flanker version, the Go/
NoGo, and the Oddball task. This might partly be due to the popularity
of these tasks and, consequently, large amount of studies using these
tasks. Furthermore, as some of these tasks might also involve vigilance/
sustained attention (e.g. Oddball task), the larger effect sizes might be
due to further deficits in sustained attention in ADHD (Barkley, 1997).
When effect sizes were compared for the different cognitive functions
(inhibitory control, (selective) attention, working memory, and error
processing), the largest effects emerged for inhibitory control. In-
hibitory control has been reported previously in numerous studies as
being particularly deficient in ADHD (Albrecht et al., 2005; Barkley,
1997; Oosterlaan et al., 1998; Quay, 1997; Sergeant, 2000, 2005).
Future studies are warranted to explore this moderator effect in relation
to developmental effects along the lifespan. Further task-related mod-
erators have been explored, such as stimulus modality: results show
that largest effect sizes were obtained for auditory stimuli. This finding
is somewhat surprising as many studies on ERPs in ADHD use tasks with
stimuli being presented visually. A possible explanation might be that
visually presented stimuli are more salient and therefore, capture more
attention, partly compensating vigilance and state regulation deficits in
ADHD. Stimuli presented via different modalities are processed in dif-
ferent brain regions, thereby activating different neural generators.
Depending on the electrode positions used for calculating ERP ampli-
tudes and latencies, some neural generators might have more impact on
the neurophysiological signal assessed than others, thereby yielding
substantial between-study differences. This points out to the im-
portance of conducting further studies using auditory stimuli compared
to visual stimuli to explore the relationship between stimulus modality
and neurophysiological deficits in ADHD in more detail taking into
account the electrode positions used for calculating ERPs. Regarding
the ISI, meta-analytic results show that for a longer time window be-
tween the presentation of each stimulus, group differences become
Table 5c
Summary of meta-analytic findings for latency moderator analyses (mixed-ef-
fects models fitted) – CNV, ERN/Ne, Pe.
Latency k QB(df, p) QW(df, p) Comparison
CNV
age n.a. n.a. n.a. n.a.
IQ n.a. n.a. n.a. n.a.
medication n.a. n.a. n.a. n.a.
comorbidity n.a. n.a. n.a. n.a.
task n.a. n.a. n.a. n.a.
cogn. function n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a.
ISI n.a. n.a. n.a. n.a.
electrodes n.a. n.a. n.a. n.a.
ERN/Ne
age n.s. n.s. n.s. n.a.
IQ n.s. n.s. n.s. n.a.
medication n.s. n.s. n.s. n.a.
comorbidity n.s. n.s. n.s. n.a.
task n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a.
ISI n.s. n.s. n.s. n.a.
electrodes n.s. n.s. n.s. n.a.
Pe
age n.s. n.s. n.s. n.a.
IQ n.s. n.s. n.s. n.a.
medication 8 7.28 (3, .06) 0.48 (5, 0.99) 4 < 3 (pos) < 1* (neg)
comorbidity n.s. n.s. n.s. n.a.
task n.s. n.s. n.s. n.a.
cogn. function n.a. n.a. n.a. n.a.
modality n.a. n.a. n.a. n.a.
ISI 8 6.83 (1, .009) 0.54 (6, 1.00) n.a.
electrodes n.s. n.s. n.s. n.a.
Note. n.a. not available. n.s. not significant. Pos – positive ES. Neg – negative ES.
Medication moderator: 1 – medicated; 2 – not medicated; 3 – washout period of
24 h; 4 – washout period of 48 h. Comorbidity moderator: 1 – yes, comorbid
disorder present; 2 – no, no comorbid disorder present. Cognitive function
moderator: 1 – Inhibition; 2 – Attention; 3 – Working memory; 4 – Error pro-
cessing. Modality moderator: 1 – visual; 2 – auditory; 3 – multimodal.
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more elevated. This result might be interpreted as reflecting difficulties
in awaiting the next stimulus presentation in the ADHD group, thereby
indicating higher levels of impulsivity symptoms. For the number of
electrodes used to assess ERPs, heterogeneous results were obtained in
the respective moderator analyses. Further studies are needed to ex-
plore if more electrodes might be associated with higher sensitivity in
detecting neurophysiological group differences between ADHD and
non-ADHD.
4.2. Practical implications: limited utility of cognitive ERPs for diagnostic
purpose, selection of individualized treatment strategies, and tracking of
therapy outcomes in ADHD
Although the current meta-analyses identified later ERPs as possible
markers of ADHD, results were characterized by substantial hetero-
geneity, not meeting criteria for clinical application of ERP-markers for
diagnostic purpose on an individual level. The heterogeneity in effect
sizes, and a number of other factors limit the practical implication of
the results. This heterogeneity on a basic neurophysiological level (e.g.
Lenartowicz and Loo, 2014) reflects the “inescapable heterogeneity” of
the ADHD phenotype (Arns and Gordon, 2014). The substantial amount
of variation in the distribution of effect sizes suggests the influence of
further relevant moderator variables, such as varying clinical profiles,
diversity of psychiatric comorbidities, varying patterns of neurocogni-
tive impairment, and varying confounds by developmental effects (e.g.
Aasen et al., 2018). More studies are needed to understand this het-
erogeneity, and to validate relevant ERP variables for multimodal
classification approaches (Mueller et al., 2011). In addition, to further
explore the sensitivity of ERPs as ADHD biomarkers, the question of
how specific these neuromarkers are needs to be addressed (Thome
et al., 2012): further studies are needed comparing different ADHD
(sub-) groups, as well as individuals with ADHD with different types of
comorbid symptoms to non-ADHD (Sur and Sinha, 2009). Additionally,
machine-learning approaches might use ERPs for identifying ADHD
subgroups based on the combination of diagnostic information from
different modalities. Beyond that, future studies should try to link ERPs
to continuous symptom dimensions adopting the RDoc approach.
Prior studies have noted the relationship between neurophysiolo-
gical processes and therapy response to medication, as well as non-
medication therapies (e.g. Banaschewski and Brandeis, 2007; atomox-
etine: Yamamuro et al., 2016a; stimulants: Ogrim et al., 2016; neuro-
feedback and methylphenidate: Janssen et al., 2016a, b; slow-cortical
potentials neurofeedback: Heinrich et al., 2004), indicating that ERPs
might be useful as objective diagnostic add-ons that are easy to assess in
a non-invasive way to predict and track therapy outcome. The current
meta-analysis suggests to (further) explicitly test the predictive value of
later ERPs as neuromarkers in a personalized medicine framework (we
are aware of a few already published, as well as ongoing studies using
EEG/ERPs to predict response to different therapeutic interventions;
e.g. Ogrim et al., 2014; ESCAlife trial, Döpfner et al., 2017).
4.3. Limitations & future directions
A few limitations of the current meta-analysis need to be acknowl-
edged. Generally, because of a small number of studies included for
some of the ERP components10, the results of the respective analyses
should be interpreted with caution. Consequently, there is an urgent
need for further studies exploring ERPs in ADHD. Although the current
meta-analyses show substantial differences in later cognitive ERP
components, further studies are warranted.
Within the current work we did not include any unpublished data.
The inclusion of unpublished data could possibly itself introduce bias as
the unpublished studies located might be an unrepresentative sample of
unpublished work and as the studies might be of lower methodological
quality (Higgins et al., 2019). Nevertheless, the current results might be
slightly biased. To address this issue, publication bias analyses were
calculated and reported. For reliably identifying biomarkers we are in
clear need of further replication studies. Open science might be a de-
sirable framework promoting such efforts. An open science approach
might reduce publication bias, thereby facilitating future meta- and
mega-analyses.
Due to the low number of studies included for some of the relevant
ERPs (especially, for earlier ERPs), moderator variables had to be ex-
plored separately. For higher validity of results and exploring the in-
terplay between influence variables, different moderators would have
been included in one (full) model. Therefore, the results are explorative
and need to be interpreted with caution. For some of the moderators,
the number of studies included per subgroup varies substantially, ren-
dering the comparison of categories less stable. As a consequence, fu-
ture studies are needed to fill the gaps of knowledge on some of the
moderator categories: first, there are only a few studies conducted on
adolescents with ADHD. Second, most of the studies are conducted in
males – a characteristic pattern obtained for studies on (psychiatric)
disorders with a higher prevalence in males compared to females
(Polanczyk et al., 2007). Most of the studies are conducted on in-
dividuals with ADHD of the combined subtype and further studies are
warranted on ADHD inattentive and hyperactive/impulsive subtypes
(Tamayo-Orrego et al., 2015). Therefore, no moderator analysis could
be conducted on ADHD subtype. In addition, there is an urgent need for
studies reporting on comorbid symptoms in individuals with ADHD, as
well as medication status (possibly, plus adherence and medication
response). Furthermore, one important research question remains un-
answered at present: how does symptom severity influence effect sizes
(Yamamuro et al., 2016b)? This question is highly relevant, especially
as the changeability of ERP components according to the clinical phe-
notype is an important criterion for the validity of biomarkers. Due to a
lack of reported information and a variety of different scales used to
assess ADHD symptom severity, this highly relevant moderator variable
could not be explored. Consequently, there is an urgent need for stan-
dardization of ADHD scales in research to compare results obtained
from different studies.
Many more moderators might be potentially relevant for ERP-dif-
ferences between individuals with and without ADHD (e.g. child- versus
adult-onset ADHD, electrode location/signal generators). Due to the
small number of studies for some of the ERPs, a lack of reporting in
primary studies, and the many fine differences in the methodological
implementation of the primary studies, we need further studies to ex-
plore the heterogeneity in effect sizes in more detail.
4.4. Conclusions
This is the first meta-analysis quantitatively summarizing relevant
literature on cognitive event-related potentials (ERPs) in ADHD across
the lifespan. In line with current executive functioning-deficit theories
of ADHD, the findings confirm that, on a group level, ADHD is asso-
ciated with specific neurophysiological alterations during cognitive
tasks, particularly during later cognitive processing-stages. Compared
to non-ADHD, individuals with ADHD show moderate differences,
mainly regarding later cognitive ERP components (P300, CNV, Pe).
Further studies are needed to fully understand the heterogeneity in
effect sizes and the influence of moderator variables to clarify the po-
tential of cognitive ERPs for supporting objective ADHD diagnosis and
neurophysiological subtyping, for selecting individualized treatment
strategies, and for tracking therapy outcomes. Clearly, identification of
conditions ensuring larger effect sizes are needed before ERPs can
10 1< k ≤ 15: Cue-P300-latency, Go-P100-amplitude & latency, Go-N100-
amplitude & latency, Go-P200-latency, NoGo-P100-amplitude, NoGo-N100-
amplitude, NoGo-P200-amplitude, NoGo-P100-latency, NoGo-N100-latency,
NoGo-P200-latency, NoGo-N200-latency, NoGo-P300-latency, ERN/Ne-latency,
and Pe-latency.
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become helpful, objective tools supporting diagnostic stratification and
precision medicine.
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